Inhibrx Biosciences, Inc.
INBX · Nasdaq · USD · Market cap $1.1B · 109 employees
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price68.97 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.94x the price, above our 2.00x limit.
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans slightly to calls (put/call 0.73)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Markup
- Insiders insiders bought, latest filing 2026-10-14
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.73, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Inhibrx Biosciences, Inc. holds its Markup at $68.97. Elevated stress, defensive posture warranted, held for 14 days.
| Phase | Markup |
| Quantitative state | Elevated stress, defensive posture warranted, held for 14 days |
| Price at the screen | $68.97 |
| Valuation | N/A trailing · -8.47 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 4.04 |
Five Screens: INBX's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 73.06% | Below 33% | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Pass |
| Receivables | 84.80% | Below 49% | Fail |
| Revenue purity | 100.00% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Inhibrx Biosciences,'s business is in a permissible area, but its interest-bearing debt is about 73% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when INBX's ethical verdict changes
Today INBX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.94x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 3 covering, consensus Strong Buy. Average target +233%.
| Forward P/E | -8.5x |
| EPS, trailing | -8.88 |
| EPS, forward | -8.76 |
| Profit margin | 0.0%currently unprofitable |
| FCF yield | -7.40% |
| Current ratio | 7.58comfortably covers its short-term bills |
| Beta | 4.04much more volatile than the market |
| Short interest, float | 0.31% |
| 52-week range | 57.30 - 155.29 |
| Market cap | $1.1B |
| Employees | 109 |
INBX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review.
Earnings landed in this window.
The framework has shifted from markdown to distribution since the last review. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Inhibrx Reports Third Quarter 2026 Financial Results Yahoo Finance · 8d ago
- Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price Yahoo Finance · 29d ago
- Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility? Yahoo Finance · 14 Oct 2026
- Inhibrx Announces Participation in Upcoming Scientific Conferences Yahoo Finance · 13 Oct 2026
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup Yahoo Finance · 2 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-14 | Lappe Mark | CEO | P - Purchase | 10,040 | $848,977 |
| 2026-09-25 | Lappe Mark | CEO | P - Purchase | 10,000 | $998,784 |
| 2026-09-16 | Kayyem Jon Faiz | Dir | P - Purchase | 5,000 | $500,000 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $127.58 | -30.0% | · | $700 | -30.0% |
| 2 months | $75.27 | +18.6% | · | $1,186 | +18.6% |
| 3 months | $69.30 | +28.8% | · | $1,288 | +28.8% |
| 6 months | $82.21 | +8.6% | · | $1,086 | +8.6% |
| 1 year | $15.37 | +480.9% | · | $5,809 | +480.9% |
| 2 years | $16.59 | +438.2% | · | $5,382 | +438.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever INBX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.